Cost-benefit evaluation of drug treatment for Alzheimer's disease

Archives of Gerontology and Geriatrics

Volumn 26, Issue SUPPL.1, 1998, Pages 275-280

  Kanowski, S ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Alzheimer's disease; Cost benefit ratio in drug tretament of dementia; Drug treatment of dementia

Indexed keywords

NOOTROPIC AGENT; PIRACETAM;

ALZHEIMER DISEASE; CAREGIVER; CLINICAL TRIAL; CONFERENCE PAPER; COST BENEFIT ANALYSIS; DISEASE COURSE; DRUG EFFICACY; HUMAN; INSTITUTIONALIZATION; META ANALYSIS; PRIORITY JOURNAL; SOCIAL SUPPORT; TREATMENT OUTCOME;

EID: 0031663872     PISSN: 01674943     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-4943(98)80039-3     Document Type: Article

References (14)

1. Ernst, R.L. and Hay, J.W. (1994): The US economic and social costs of Alzheimer's disease revisited. Am. J. Public Health, 84, 1261-1264.
2. Hu, T., Huang, L. and Cartwright, W. (1986): Evaluation of the costs of caring for the senile demented elderly: a pilot study. Gerontologist, 26, 158-163.
3. Huang, T., Cartwright, W. and Hu, T. (1988): The economic costof senile dementia in the United States, 1985. Publ. Helath Rep., 103, 3-7.
4. Knapp, M.J., Knopman, D.S., Solomon, P.R., Pendlebury, W.W., Davis, C.S. and Gracon, S.I. (1994): A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group. J. Am. Med. Assoc., 271, 985-991.
5. Knopman, D., Schneieder, L., Davis, K., Talwalker, S., Smith, F., Hoover, T. and Gracon, S.I. (1996): Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality, Tacribe Study Group. Neurology, 47, 166-177.
6. Lubeck, D.P., Matonson, P.D. and Bowe, T. (1994): Potential effect of tacrine on expenditures for Alzheimer's disease. Med. Interface, 7, 130-138.
7. Max, W. (1996): The cost of Alzheimer's disease. Pharmaco-Economics, 9, 5-10.
8. Mittelman, M.S. Ferris, H.F., Steinberg, G., Shulman, E., Mackell, J.A., Ambinder, A. and Cohen, J. (1993): An intervention that delays institutionalization of Alzheimer's disease patients: Treatment of spouse-caregivers. Gerontologist, 33, 730-740.
9. Mittelman, M.S., Ferris, H.F., Shulman, E., Steinberg, G., Ambinder, A., Mackell, J.A. and Cohen, J. (1995): A comprehensive support program: Effect on depression in spouse-caregivers of AD patients. The Gerontologist, 35, 792-802.
10. Mundell, I. (1993): Is tacrine worth the price? Inpharma, 910, 3-4.
11. Schulenburg, J.-M., Horn, R., Grobe-Einsler, R., Bernhardt, D., Möller, H.-J. and Schulenburg, I. (1995): Kostenanalyse der Behandlung hirnleistungsgestörter Patienten. Geriatr. Forsch., 5, 31-40 (in German).
12. Stommel, M., Collins, C.E. and Given, B.A. (1994): The costs of family contributions to the care of persons with dementia. Gerontologist, 34, 199-205.
13. Vlietinck, R., Van Loen, M.D., Van de Broele, H. and Tormans, G. (1993): Retrospective estimate of the nursing cost of autonomy impairment and cost benefit in clinical trials: Feasibility and application of piracetam in demented elderly patients. Advances in Therapy, 10, 226-244.
14. Weinberger, M., Goldt, D.T. and Divine, G.W. (1993): Expenditures in caring for patients with dementia who live home. Am. J. Public Health, 83, 338-341.